G-protein coupled receptors (GPCR) are the largest single class of cell-surface receptors, with over 800 genes encoded in the human genome. GPCRs have broad physiological and patho-physiological roles with diverse ligands including amines, small proteins, lipids, and neurotransmitters. Approximately 40% of all approved drugs are targeting GPCRs. Traditionally, GPCRs are considered to be non-tractable for therapeutic antibody drug development.
The co-founders of REMD, Hai Yan and Tom Boone, pioneered and established the first ever GPCR antibody discovery platform while employed at Amgen which led to development of Aimovig™ and AMG477 (now REMD477). Since the founding of REMD Biotherapeutics the team has streamlined the entire process and have identified and characterized antibody candidates against multiple validated GPCR targets implicated in immuno-oncology and endocrine disorders.